Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Substance dependence" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Drug addiction is a chronic, often relapsing brain disease that causes compulsive drug seeking and use, despite harmful consequences to the drug addict and those around them.
Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
Owner:AVENTIS PHARMA INC
Thienoisoxazolyl-and thienylpyrrazolyl phenoxy substituted propyl derivatives useful as d4 antagonists
The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
Owner:AVENTISUB II INC
Methods for Treating Dependence
Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.
Owner:BIOTIE THERAPIES INC
Application of c-Kit serving as drug addiction treatment target
ActiveCN105974131AEffective treatmentEffective excitabilityDisease diagnosisBiological testingSubstance dependenceAddiction treatment
The invention discloses new application of c-Kit, and provides application of the c-Kit serving as a drug target in screening of drugs for treating drug addiction and application of the c-Kit in screening of drugs for treating substance dependence addiction psychological craving and excitability of addiction drugs. A classical rat sensitization and conditioned place preference animal model for evaluating addiction is adopted for observing influences of an inhibitor imatinib of the c-Kit on renewed behaviors after formation and withdrawal of rat sensitization behavior expression and conditioned place preferences respectively, the inhibiting effect of imatinib on morphine addiction and an anti-relapse effect after withdrawal of morphine addiction is achieved are evaluated, and application of an acting target c-Kit receptor serving as the drug treatment target of drug addiction is determined. The c-Kit is good in effect and is expected to fundamentally treat drug addiction.
Owner:WUHAN UNIV
Methods for Treating Dependence
Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.
Owner:BIOTIE THERAPIES INC
Liquid naloxone spray
ActiveUS10617686B2Organic active ingredientsPharmaceutical delivery mechanismSubstance dependenceOpioid overdose
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
Owner:HIKMA PHARMA USA INC
Therapeutic agents for drug/substance dependence
InactiveUS20060025434A1Excellent in ability to penetrate into brainAvoid dependenceBiocideNervous disorderSubstance dependenceMedicine
Therapeutic agents for drug / substance dependence containing a compound represented by the following compound: as an active ingredient. The therapeutic agents are excellent in the capability to penetrate into the brain, can promote the recovery from the state of psychological and physical dependent on dependence drugs / substances, can inhibit the craving and exacerbation, and are useful for treating drug / substance dependence and drug / substance dependence patients.
Owner:TORAY IND INC
Genetic polymorphisms and substance dependence
The invention encompasses a method for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating the response of a subject to a substance cessation treatment.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Liquid naloxone spray
ActiveUS10973814B2Organic active ingredientsPharmaceutical delivery mechanismSubstance dependenceOpioid overdose
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
Owner:HIKMA PHARMA USA INC
Liquid naloxone spray
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
Owner:HIKMA PHARMA USA INC
Liquid naloxone spray
ActiveUS10722510B2Organic active ingredientsInorganic non-active ingredientsSubstance dependenceOpioid overdose
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention both intranasally and sublingually to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally and sublingually the naloxone formulations of the present invention.
Owner:HIKMA PHARMA USA INC
Methods for treating substance dependence
The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of gabapentin, or pharmaceutically acceptable salt thereof.
Owner:THE SCRIPPS RES INST
Materials and Methods Related to Dopamine Dysregulation Disorders
The present invention provides methods of identifying an increased risk of a dopamine dysregulation disorder in a human subject, including identifying increased risk of dementia, Parkinson's disease, Huntington's, epilepsy, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, alcoholism, obesity, addiction disorders, pathological gambling, attention deficit hyperactivity disorder, bipolar disorder, Tourette syndrome, substance dependence, sub stance abuse, substance overdose, and substance-related death.
Owner:OHIO STATE INNOVATION FOUND
Therapeutic agent for substance dependence
The present invention provides a therapeutic agent for substance dependence, which prevents relapse / recurrence of compulsive substance-taking behavior based on craving for addictive substances such as stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, cocaine, hemp, cannabis, alcohol, or volatile organic solvents. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is useful as a therapeutic agent for substance dependence, which prevents relapse / recurrence of compulsive substance-taking behavior associated with craving for addictive substances.
Owner:KYUSHU UNIV +1
Use of hirsutine in preparing anti-addictive drug
The invention relates to a drug containing a heterocyclic system of a hexatomic ring with nitrogen as a heteroatom, in particular to an application of hirsutine in preparing a drug for preventing and treating opioid substance addiction or amphetamine substance dependence. The drug is composed of the hirsutine and a pharmaceutically acceptable auxiliary material, wherein, the hirsutine content is 5-85%. The drug is oral preparation such as a tablet or a capsule and the like.
Owner:SOUTHERN MEDICAL UNIVERSITY
Genetic polymorphisms and substance dependence
InactiveUS20110143344A1Increased riskOrganic active ingredientsSugar derivativesSubstance dependenceGene cluster
The invention encompasses methods for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating the response of a subject to a substance cessation treatment.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
Owner:AVENTIS PHARMA INC
Method of treatment
A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula Ior its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Owner:DAVIS PATRICIA C +4
Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists
The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
Owner:AVENTISUB II INC
Use of hirsutine in preparing anti-addictive drug
The invention relates to a drug containing a heterocyclic system of a hexatomic ring with nitrogen as a heteroatom, in particular to an application of hirsutine in preparing a drug for preventing and treating opioid substance addiction or amphetamine substance dependence. The drug is composed of the hirsutine and a pharmaceutically acceptable auxiliary material, wherein, the hirsutine content is 5-85%. The drug is oral preparation such as a tablet or a capsule and the like.
Owner:SOUTHERN MEDICAL UNIVERSITY
Heterocyclic m-glu5 antagonists
Compounds I(R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotricyclic group containing from 1 to 5 heteroatoms selected from N, O and S;R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S;R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotricyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group;each R4, independently for each position capable of substitution, is H or C1-C6 alkyl;R5 is H, halogen or C1-C6 alkyl;m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and is an optional double bond)and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and fragile X syndrome disorders.
Owner:RECORDATIE IRELAND LTD
Therapeutic Agent for Substance Dependence
The present invention provides a therapeutic agent for substance dependence, which prevents relapse / recurrence of compulsive substance-taking behavior based on craving for addictive substances such as stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, cocaine, hemp, cannabis, alcohol, or volatile organic solvents. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is useful as a therapeutic agent for substance dependence, which prevents relapse / recurrence of compulsive substance-taking behavior associated with craving for addictive substances.
Owner:KYUSHU UNIV +1
Method for treating drug or alcohol dependency
PendingCN113573711ASmall doseOrganic active ingredientsNervous disorderSubstance dependenceAddictive behavior
Owner:イーサーセラピューティクスインコーポレイテッド
Psychiatry auxiliary diagnosis system
PendingCN112201339AEffective diagnosisEfficient diagnosis resultsMedical automated diagnosisSubstance dependenceAIDS diagnosis
The invention discloses a psychiatry auxiliary diagnosis system, and the system comprises an information acquisition module used for acquiring symptom information of a patient; a preprocessing modulewhich is used for standardizing the symptom information to obtain input information conforming to a preset format; a symptom classification module which is used for performing symptom classification on the input information conforming to the preset format to obtain a symptom classification result, wherein the symptom classification result comprises normality, depression, anxiety, psychosis, material dependence and compulsion; a degree classification module which is used for carrying out degree classification on the symptom classification result to obtain a degree classification result, whereinthe degree classification result comprises normality, lightness, moderate degree and severity. According to the technical scheme provided by the invention, the mental state of the patient can be efficiently and intelligently detected, so a doctor is assisted in diagnosis.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Method of treatment
Owner:ASTRAZENECA AB
Liquid naloxone spray
ActiveUS20200093818A1Improved pharmacokinetic parameterOrganic active ingredientsPharmaceutical delivery mechanismSubstance dependenceOpioid overdose
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
Owner:HIKMA PHARMA USA INC
Agent for prophylaxis or treatment of substance abuse and dependence
The present invention provides an agent for the prophylaxis or treatment of substance abuse and dependence, which contains a compound of the formula (I) represented by (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, or a pharmaceutically acceptable salt thereof as an active ingredient.
Owner:MITSUBISHI TANABE PHARMA CORP
Methods and compositions for the treatment of opioid dependence and for the treatment of pain
PendingUS20220031798A1Prevent relapseReduce the possibilityNervous disorderOrganic chemistrySubstance dependencePharmaceutical drug
The present invention relates to methods of treating opioid dependence, enhancing the treatment of opioid dependence, treating opioid withdrawal, or alleviating one or more opioid withdrawal symptoms in a subject, preventing or reducing the likelihood of opioid dependence relapse in a subject treated for opioid dependence, reducing the vulnerability of a subject to develop opioid dependence in adulthood following opioid exposure during adolescence, or treating pain in a subject, comprising administering a therapeutically effective amount of a N-methyl-D-aspartate receptor (NMDA) partial agonist to the subject. The present invention further relates to compositions comprising an NMDA partial agonist for use with the aforementioned methods.
Owner:DUKE UNIV
Detection method of th gene snp locus associated with opioid dependence and its application
ActiveCN110331192BTyping is easyTyping fastMicrobiological testing/measurementSubstance dependenceGene
Owner:XI AN JIAOTONG UNIV
Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
ActiveUS20220331299A1More efficaciousToxic reductionOrganic active ingredientsNervous disorderCompulsive disordersSubstance dependence
There is provided a compound of formula (I), wherein L1 to L3′, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/4019f449-a681-4976-9bcc-23a7432d44b5/US20220331299A1-C00001.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/4019f449-a681-4976-9bcc-23a7432d44b5/US20220331299A1-C00002.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/4019f449-a681-4976-9bcc-23a7432d44b5/US20220331299A1-C00003.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
Owner:CHRONOS THERAPEUTICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com